Nonetheless, upregulation of NEDD4 resensitized multiple myeloma cells to bortezomib treatment via ubiquitination of Akt and degradation of pAkt-Ser473, while downregulation of NEDD4 resulted in bortezomib resistance in multiple myeloma cells[42]. The gene discussed is NEDD4; the disease is AL amyloidosis.